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1120-63 Comparison of Intracoronary Bolus Injection and 
Intracoronary Continuous Infusion Methods for 
Inducing Hyperemia
Tae-Young Choi, Seung-Jea Tahk, Myeong-Ho Yoon, So-Yeon Choi, Min-Cheul Kim, 
Heung –Mo Yang, Jung-Hyun Choi, Zhen-Guo Zheng, Long Qi, Byoung-Joo Choi, Hyuk-
Jae Chang, Gyo-Seung Hwang, Joon-Han Shin, Byung-il W. Choi, Ajou University 
School of Medicine, Suwon, South Korea
Background: The method to induce coronary hyperemia with maximal and steady state
is important to evaluate microvascular circulation by coronary flow reserve(CFR) and
fraction flow reserve(FFR). We studied the method of induing hyperemia with intra-coro-
nary(IC) adenosine bolus injection and continuous infusion.
Methods: CFR was evaluated in thirty-six coronary lesions(LAD 23, LCX 5, RCA 8) in 23
patients(male 18, mean 58±12 y; SA 2, UA 12, AMI 9) and FFR was evaluated in twenty
lesions(LAD 13, LCX 6, RCA 1) in 10 patients(male 8, mean 60±11 y; SA 1, UA 7, AMI
2). To induce maximal coronary hyperemia, two methods were applied to same patient;
Method A(IC adenosine bolus injection(RCA 24µg, LCA 48µg)) and Method B(IC ade-
nosine continuous infusion(240µg/min). CFR was defined as a ratio of hyperemic(hAPV)
to baseline APV(bAPV). FFR was defined as a ratio of mean aortic pressure to mean
coronary pressure of distal part to lesion during maximal hyperemia. Hyperemic average
peak velocity(hAPV, cm/sec), CFR and FFR were compared with paired t-test in two
methods.
Results: All patients were tolerable during maximal hyperemic period. During maximal
coronary hyperemia, heart rate and mean blood pressure were not different between two
methods. Transient AV block occurred in 2 patients with method A and in 2 same patients
with method B. The duration of maintenance of hyperemia was mean 24.6±5.4 seconds
in method A and all patient except 2 patients were maintained stable hyperemia with
method B during continuous infusion of adenosine. CFR and hAPV were significantly
higher by using of method B than those of method A(3.4±2.1 vs. 2.9±1.2, p=.01 ;
52.5±23.4 vs. 45.7±19.9, p<0.01, respectively). FFR was significantly lower by using of
method B than that of A(0.76±0.17 vs. 0.80±0.15, p<0.01).
Conclusion: Compared with intracoronary adenosine bolus injection method(24-48µg),
intracoronary adenosine continuous infusion method(240µg/min) was more effective and
stable for inducing maximal hyperemia.
1120-64 High Left Ventricular Mass Does Not Limit the Utility of 
Fractional Flow Reserve for the Physiologic 
Assessment of Lesion Severity
Adnan K. Chhatriwalla, Kurt G. Barringhaus, Michael Ragosta, Eric R. Powers, J. 
Christopher McClish, Joshua Fischer, Andrew H. Bishop, Lawrence W. Gimple, Ian J. 
Sarembock, C. Joon Choi, Christopher M. Kramer, Habib Samady, The University of 
Virginia, Charlottesville, VA
Background: Fractional Flow Reserve (FFR) has been shown to be a useful invasive
physiologic index of coronary lesion severity. Increased left ventricular mass (LVM) can
impair microvascular reserve. However, whether increased LVM sufficiently impacts flow
reserve to effect clinical FFR measurements is not known.
Methods: LVM was calculated from contrast left ventriculography in 84 patients using a
modified Rackley method, which correlated well with LVM measured by cardiac MRI in 17
patients who had undergone both tests (r=0.80, p<0.001). The cohort was divided into
normal and high left ventricular mass index (LVMI) groups based on published normal
values. Cardiac risk factors and lesion FFR were compared in 22 vessels of patients with
high LVMI to 62 angiographically matched lesions in vessels of patients with normal
LVMI.
Results: LVMI was 84±21 g/m2 and 126±21 g/m2 in the normal and high LVMI groups,
respectively. There were no differences in age (59 vs 58 yrs, p=ns), presence of diabetes
(26% vs 27%, p=ns), hypertension (60% vs 73%, p=ns), dyslipidemia (56% vs 64%,
p=ns) or angiographic LVEF (58% vs 62%, p=ns) between groups. Importantly, in lesions
with similar angiographic characteristics, there was no difference in FFR between groups.
(Table). 
Conclusion: FFR of lesions in patients with high LVM is no different to FFR of angio-
graphically similar lesions in patients with normal LVM. These findings suggest that
increased LVM should not limit the utility of FFR as a physiologic index of lesion severity.
1120-65 Emboli Protection Improves Thrombolysis in Myocardial 
Infarction Perfusion Score in Saphenous Vein Graft 
Intervention
Jose E. Exaire, Cameron Haery, Deepak L. Bhatt, Sorin J. Brener, Stephen G. Ellis, Jay 
S. Yadav, Eric J. Topol, Cleveland Clinic Foundation, Cleveland, OH
Background: Use of emboli protection devices (EPD) during saphenous vein graft per-
cutaneous coronary intervention (SVG-PCI) has been proven to reduce major adverse
cardiac events (MACE) specifically the composite of myocardial infarction, urgent target
vessel revascularization, and death. However, the impact of EPD on the microcirculation
using TIMI myocardial perfusion score (TMP) has not been fully characterized. We
sought to analyze TMP in both unprotected- and EPD- SVG-PCI and its impact on 30-day
MACE.
Methods: From August 2001 to December 2002, 305 patients had a SVG-PCI suitable
for EPD; 247 (81%) had an angiogram appropriate for TMP evaluation. Of those, 49
(20%) had an EPD deployed during the coronary intervention. Both groups were similar
regarding most demographic features, but use of GP IIb/IIIa inhibitors was more frequent
in the EPD group (87% vs 74% P=0.007).
Results: TMP 3 score was obtained in 87% of the EPD group vs 56% of the unprotected
SVG-PCI (P<0.01) (Figure 1). MACE was 4.2% in the EPD group vs. 8.1% in the unpro-
tected SVG-PCI group (P=0.04). Unprotected SVG-PCI patients with TMP scores lower
than 3 had a trend towards increased total post-procedural CK (177 U/L vs 133 U/L
P=0.07), and CK-MB (21 ng/mL vs 6 ng/mL P=0.07).
Conclusions: EPD SVG-PCI improves TMP score when compared to unprotected SVG-
PCI. This finding was associated with a decrease in post-procedural MACE. 
1120-66 Early Saphenous Vein Graft Failure: A Predictor of Poor 
Outcomes After Percutaneous Coronary Intervention
Daniel Arthur Canos, Gary S. Mintz, Ben Y. Rock, Esteban Escolar, Natalie Gevorkian, 
Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Neil J. Weissman, Washington 
Hospital Center, Washington, DC
Background: While most saphenous vein grafts (SVGs) remain patent for approximately
ten years, up to 15-20% of SVGs become occluded within the first year of implantation.
The results following percutaneous coronary intervention (PCI) of early compared to late
graft failure are not well known.
Methods: We identified 100 pts (121 lesions) with early (< 1yr) SVG failure and 200 pts
(289 lesions) with late (> 1yr) SVG failure that underwent PCI. Pts were matched for
hypercholesterolemia and diabetes. Data on procedure, post-procedure coronary
angiography, and 1-year follow-up were analyzed. Angiographic measurements included
reference size, final minimum lumen diameter (MLD), lesion length, and final diameter
stenosis (DS).
Results: Early and late failure graft age was 6.0 ± 2.9 months and 105.4 ± 50.8 months
respectively. The early group had smaller references (2.78± 0.81 vs 3.30± 0.76 mm, p<
0.01), smaller final MLD (2.33 ± 0.96 vs 2.91 ± 0.85, p< 0.01), and larger final DS (16.6 ±
24% vs 11.6 ± 18.1%, p= 0.03).
Procedural success was 96% in both groups; only 1 pt in each group had an in-hospital
QMI, and 13.4% of early and 13.5% of late pts had a Non-Q MI (CKMB>5xNL). Stent use
was not related to one-year target vessel revascularization (TVR) 29.8% in the stent
group and 32.1% in the no stent group. However, the early SVG failure group had a sig-
nificantly higher rate of TVR at one-year (38.6% vs 26.6%, p= 0.04). On multivariate
analysis examining stent use, time of graft closure, and final DS; early graft closure was
the strongest predictor of TVR (p= 0.06)
Conclusion: Despite a high rate of procedural success, 1-year TVR is higher in SVGs
with early failure. Further investigation with novel interventional devices or techniques is
necessary in this high risk population to eventually improve long term outcomes. 
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1121-47 Bone Marrow and Neural Crest Derived Cells Contribute 
to In-Stent Restenosis
Gerhard Bauriedel, Dirk Skowasch, Alexander Jabs, René Andrié, Berndt Lüderitz, Heart 
Center University of Bonn, Bonn, Germany
Objective: In in-stent restenosis (ISR), a significant number of intimal mesenchymal
cells remain unidentified. Also, there is ongoing controversy on the origin of neointimal
cells. Therefore, the objective of the present study was to assess cellularity, cell type and
origin of neointimal cells.
Reference 
Diameter 
(mm)
Minimum 
Luminal 
Diameter (mm)
Percent 
Diameter 
Stenosis (%)
Lesion 
length(m
m)
FFR
High 
LVMI(n=22)
3.3±0.5 1.3±0.6 61±13 14.2±7 0.79±0.12
Normal 
LVMI(n=62)
3.1±0.7 1.3±0.6 62±13 14.3±7 0.78±0.16
p-value ns ns ns ns ns
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Methods: Atherectomy probes from 17 patients with coronary ISR (n=10; time post
stenting 5±3 months) and with peripheral ISR (n=7; 7±3 months) versus those from 10
patients with primary lesions were immunohistochemically examined for the presence of
the determinants CD34, AC133, S100, GFAP, NSE, NGFR and α-smooth muscle (SM)
actin followed by computer-assisted morphometry.
Results: ISR probes demonstrated pronounced hypercellularity (942±318 cells/mm2)
compared to primary lesions (347±120 cells/mm2, P<0.001). α-SM actin positive cells
occupied 67% of intimal cells in ISR. Expression of endothelial progenitor cells (EPCs;
CD34: 7.1±2.5% positive/total cells vs. 0.6±0.7%, P<0.001; AC133: 7.0±3.4% vs.
1.0±0.7%, P<0.001), dendritic cells (DCs; S100: 9.8±5.6% vs. 1.4±1.1%, P<0.001) and
neural-crest derived cells (NCCs; GFAP: 7.9±2.4% vs. 3.1±1.0%; NSE: 4.4±2.6% vs.
1.3±1.6%; NGFR: 4.2±2.5% vs. 1.1±0.7%; each P<0.001) was significantly increased in
ISR compared to primary lesions. Importantly, double immunostaining did not demon-
strate α-SM actin positive cells exhibiting markers of EPCs, DCs or NCCs. With respect
to EPC immunolabelling, AC133 could be detected in a subset of CD34 positive cells,
whereas all cells stained by AC133 also expressed the CD34 antigen. Quantitatively,
both EPC marker proteins revealed a significant correlation (r=0.57, P<0.01). Consis-
tently, there were a only few cells found in ISR atherectomy probes that demonstrated
coexpression of EPC, DC or NCC markers. Our data show residual 5-15% yet unidenti-
fied neointimal cells, that were not stained by any specific cell type marker used.
Conclusions: Bone-marrow and neural-crest derived cells, the most dendritic cells, are
consistently found in ISR, whereas α-SM actin positive cells constitute the largest intimal
cell pool. These data clearly indicate the presence of primarily extravascular cells in
human ISR.
1121-48 Preprocedural Plasma Levels of C-Reactive Protein and 
Interleukin-6 Do Not Predict Late Coronary 
Angiographic Restenosis After Elective Stenting
Amit Segev, Saleem Kassam, Christopher E. Buller, Herbert K. Lau, John D. Sparkes, 
Philip W. Connelly, Peter H. Seidelin, Madhu K. Natarajan, Eric A. Cohen, Bradley H. 
Strauss, St. Michael's Hospital, Toronto, ON, Canada, Vancouver Hospital and Health 
Sciences Centre, Vancouver, BC, Canada
Aims Inflammatory markers may serve as an important prognostic predictor in patients
with coronary heart diseases. In patients undergoing coronary interventions, it has been
shown that baseline C-reactive protein (CRP) could predict late adverse cardiac events
(clinical restenosis). However, only a few small studies have examined the relation with
angiographic restenosis. In a large number of patients, we examined whether baseline
plasma levels of CRP and IL-6 may predict late coronary angiographic restenosis after
elective coronary stenting.
Methods Pre-procedural plasma levels of CRP and IL-6 were measured in 216 patients
with stable angina pectoris undergoing elective coronary stenting who were included in
the MedStent and DISTINCT trials. Angiographic follow-up was performed in all patients
at 6 months. Angiographic restenosis was defined as diameter stenosis >50% by QCA at
6 months.
Results Baseline CRP levels were 6.45±0.78 mg/L versus 5.24±1.16 mg/L in the patent
and restenosis groups, respectively (p=0.64). IL-6 levels were 0.46±0.03 ng/L versus
0.40±0.07 ng/L in the patent and restenosis groups, respectively (p=0.50). CRP levels
were obtained again at the time of angiographic follow-up and were found to be similar in
both groups (2.89±0.29 mg/L versus 2.61±0.63 mg/L, p=0.72). Moreover, in a sub-group
of 43 patients, serial blood samples were obtained at several time points after the proce-
dure up to 6 months. Both CRP and IL-6 plasma levels were increased significantly in
response to the procedure. CRP levels peaked at 3 days (11.27±1.53 mg/L versus
4.26±0.72 mg/L at baseline, p<0.001). IL-6 levels reached maximum values after 24
hours (1.08±0.14 ng/L versus 0.53±0.08 ng/L at baseline, p<0.001). However, in this sub-
group of patients, neither peak CRP nor IL-6 levels were found to predict late angio-
graphic restenosis.
Conclusion Coronary stenting is associated with transient increases in both CRP and
IL-6 levels. However, pre-procedural CRP and IL-6 levels do not predict late coronary
angiographic restenosis.
1121-49 Homocysteine Levels and Methylenetetrahydrofolate 
Reductase Polymorphisms Are Not Associated With 
Restenosis After Coronary Artery Stenting
Werner Koch, Marc Burghartz, Harald Lengnick, Petra Hoppmann, Siegmund Braun, 
Klaus Kölling, Albert Schömig, Adnan Kastrati, Deutsches Herzzentrum München, 
Munich, Germany
Background: Elevated levels of plasma homocysteine have been associated with athero-
thrombotic diseases.Two polymorphisms, 677C/T and 1298A/C, of methylenetetrahydro-
folate reductase (MTHFR) interfere with enzyme activity and, therefore, may influence
homocysteine levels. We examined the possibility that elevated homocysteine and the
polymorphisms of MTHFR are associated with restenosis and adverse clinical outcomes
after stenting in coronary arteries.
Methods: The study population consisted of 800 patients with symptomatic coronary
artery disease who were treated with stent implantation. Angiographic restenosis (50%
or greater diameter stenosis at 6-month follow-up) and clinical restenosis (need for target
vessel revascularization during the first year after stenting) were evaluated.
Results: Six-month follow-up angiography was done in 601 patients (75.1%). The rates of
angiographic or clinical restenosis were not significantly different between patients with
low or high homocysteine levels or among the genotypes of the MTHFR polymorphisms
(Table). Late lumen loss and loss index were not associated with homocysteine levels or
the MTHFR genotypes (Table). The one-year incidence of death or MI was not depen-
dent on homocysteine concentrations or the genotypes (Table).
Conclusions: Our results suggest that elevated homocysteine levels or the MTHFR poly-
morphisms 677C/T and 1298A/C are not associated with restenosis and adverse clinical
outcomes after stenting in coronary arteries.
1121-50 Peroxisome Proliferator-Activated Receptor Gamma 
Gene Polymorphisms and Risk of Restenosis After 
Coronary Artery Stenting in Patients With Diabetes
Werner Koch, Vanessa Jung, Elena Michou, Olga Gorchakova, Klaus Tiroch, Nicolas von 
Beckerath, Albert Schömig, Adnan Kastrati, Deutsches Herzzentrum München, Munich, 
Germany
Background: Several lines of evidence suggest that activation of peroxisome prolifera-
tor-activated receptor gamma (PPARγ) may interfere with restenosis. Polymorphisms of
the PPARγ gene were found to be associated with coronary artery disease and diabetes.
We examined the role of the 34C/G and 1431C/T polymorphisms of the PPARγ gene in
restenosis after stenting in patients with diabetes.
Methods: The study population consisted of 752 diabetic patients with symptomatic cor-
onary artery disease who were treated with stenting. Restenosis was defined as a 50%
or greater diameter stenosis six months after the intervention. Clinical outcome mea-
sures (death, myocardial infarction, restenosis-driven reintervention) were evaluated dur-
ing the first year after the intervention. For analysis, patients homozygous for the
common allele were compared with the carriers of the rare allele.
Results: Restenosis rates and continuous measures of restenosis (late lumen loss, loss
index) were not significantly different between the PPARγ genotype groups (Table). In
addition, the one-year incidences of death or myocardial infarction and reintervention
were not significantly different between the groups (Table).
Conclusions: Our results suggest that the PPARγ gene polymorphisms 34C/G and
1431C/T are not associated with restenosis and adverse clinical outcomes after coronary
artery stenting in diabetic patients.
1121-51 SU11218, a Platelet-Derived Growth Factor Receptor 
and Vascular Endothelial Growth Factor Receptor 2 
Inhibitor Blocks Adventitial Angiogenesis and Prevents 
Intimal Hyperplasia After Coronary Stenting in a Porcine 
Model
Asim N. Cheema, Tony S. Hong, Jennifer Dietrich, David Holdsworth, Ken Lipson, 
Bradley H. Strauss, St. Michael's Hospital, Toronto, ON, Canada, John P. Robarts 
Research Institute, London, ON, Canada
Background: Balloon angioplasty has been shown to produce an angiogenic response in
the arterial adventitia, which is associated with restenosis in the injured segment. We
hypothesized that stenting will result in a similar but more prominent adventitial angio-
genic response and inhibition of this angiogenic response with a tyrosine kinase inhibitor
will prevent intimal hyperplasia and restenosis after coronary stenting.
Methods: We performed coronary stenting of the left circumflex artery in 20 Yorkshire
pigs. Pigs were treated with placebo or SU11218, a tyrosine kinase receptor inhibitor that
blocks the activity of PDGFR and VEGFR2, which was administered subcutaneously (5
mg/kg) twice weekly for four weeks. Intravascular ultrasound was performed immediately
after stenting and at four weeks for determination of lumen and intimal cross sectional
areas. Adventitial microvessels were assessed ex vivo in the stented segments by micro-
scopic computed tomography at a resolution of 16 um.
Results: The mean plasma levels for SU 11218 were 1.9-5.8ng/ml. At 4 weeks, arterial
stenting resulted in a marked angiogenic response in vascular adventitia and the number
of adventitial microvessels strongly correlated with the amount of instent intimal hyperpla-
Angiographic and clinical outcomes after coronary stenting according to MTHFR 
polymorphisms
677C
C
677C
T
677T
T
P 
value
1298A
A
1298A
C
1298C
C
P 
value
Angiographic restenosis 
rate (%)
26.0 23.5 26.9 0.75 24.4 25.9 24.0 0.90
Clinical restenosis rate 
(%)
19.5 17.1 23.3 0.37 17.6 18.6 24.7 0.27
Late lumen loss (mm) 1.01 1.04 1.05 0.79 1.02 1.05 0.98 0.69
Loss index 0.60 0.65 0.63 0.71 0.63 0.61 0.68 0.70
Death or MI, 1y (%) 3.2 3.0 6.7 0.22 3.5 3.9 2.1 0.69
Angiographic and clinical outcomes after coronary stenting according to the 
PPARgamma polymorphisms
34CC 34CG + 
34GG
P 
value
1431CC 1431CT + 
1431TT
P 
value
Restenosis rate (%) 35.4 36.2 0.88 35.4 36.3 0.85
Late lumen loss (mm) 1.22 1.30 0.34 1.23 1.24 0.89
Loss index 0.43 0.44 0.74 0.43 0.44 0.80
Death or myocardial 
infarction, 1y (%)
8.3 8.6 0.89 8.0 9.7 0.46
Restenosis-driven 
reintervention, 1y (%)
16.6 14.9 0.60 16.8 14.5 0.47
